ABBV Dec 2025 200.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:59AM EST. Market open.
Loading interactive chart…
- Insider Monkey
Here’s Why AbbVie (ABBV) Rose in Q3
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. After a robust first half of the year, the S&P 500 Index declined 3.3% in the third quarter, leaving the market up 13.1% through the first nine […]
- Zacks
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
- Simply Wall St.
Optimism for AbbVie (NYSE:ABBV) has grown this past week, despite five-year decline in earnings
If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share...
© 2023 Yahoo. All rights reserved.